Gabapentin Tablet, Film Coated
Product Images NDC 71335-2819

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2819). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

An illustration showing the formula for calculating creatinine clearance (CLCr). The formula accounts for age in years, weight in kilograms, serum creatinine in mg/dL, and includes an adjustment factor of 0.85 for female patients.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1,' showing mean pain scores over 8 weeks for two groups: placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. Two distinct periods, a 4-week dose titration and a 4-week fixed dose, are indicated. Gabapentin shows a gradual decrease in mean pain scores over time compared to placebo.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

A line graph titled "Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2" showing mean pain scores on the y-axis (0 to 10) and weeks on the x-axis (Baseline to 7). It compares placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day over a 3-week dose titration period and a 4-week fixed dose period, illustrating changes in mean pain scores over time.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares response rates between placebo (PBO) and varying dosages of gabapentin (GBP 1800, 2400, 3600 mg) across two studies, showing higher proportions of responders in gabapentin groups with statistical significance indicated (p<0.01, p<0.001).*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot graph showing the responder rate difference (%) between gabapentin and placebo by daily dose (mg) in patients aged 12 years or older with partial seizures. The graph presents data points from three adjunctive therapy studies labeled as study a, study b, and study c, with doses ranging roughly from 600 to 1800 mg and corresponding response differences from 0 to 22%.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of gabapentin showing a cyclohexane ring bonded to amino and carboxyl functional groups.*

FDA Label Image

Label (Lbl713352819)

Gabapentin Tablets, USP 800 mg film-coated oral tablet label. The label shows the NDC 71335-2819-1 and indicates a package of 90 tablets. It is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Aurobindo Pharma Limited. Storage and safety instructions, a QR code for prescribing information, and child-resistant container instructions are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.